Development asset linked to BioXcel Therapeutics in public FDA and regional records.
pharma · Agitation · Agitation,Psychomotor · BTAI
BioXcel Therapeutics
BioXcel Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US HQ
2017 Founded
56 Employees
Public company Type
BTAI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US
- Founded
- 2017
- Employees
- 56
- Programs
- 17
- Drugs
- 9
- Patents
- 18
BioXcel Therapeutics pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
BioXcel Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
dexmedetomidine
Nervous system (N05)Nervous system (N05) compound in BioXcel Therapeutics's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
US regulatory status: approved. Molecular target: Soluble guanylate cyclase.
- Target
- Soluble guanylate cyclase
- Mechanism
- Soluble guanylate cyclase activator
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
pirfenidone
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to BioXcel Therapeutics in public FDA and regional records.